Why Cognition Therapeutics, Inc.’s (CGTX) Stock Is Up 5.69%
As of Monday, November 02, Cognition Therapeutics, Inc.’s CGTX share price has surged by 5.69%, which has investors questioning if this is right time to sell.Michael Rose
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Jenna Brashear
Rosalio Madrigal
Jenna Brashear
Jenna Brashear
| Share Statistics | CGTX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $64.7 | $447.9 | 19% |
|
| Shares Out (Mil) | 95.1 | 46.7 | 61% |
|
| Institutional Ownership | 91.2% | 80.9% | 59% |
|
| Float (Mil) | 87.5 | 46.8 | 57% |
|
| Beta | 1.80 | 0.74 | 88% |
|
| Avg Daily Volume (000s) | 376 | 342 | 53% |
|
| Price Change (52-week) |
(60.5%) | 54.7% | 16% |
|
| Growth | CGTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | (24.7%) | (1.6%) | 17% |
|
| EPS (5yr) | 57.7% | 15.0% | 95 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (48.7%) | (15.1%) | 8% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.045) | ($0.185) | ($0.185) | |
| Month Ago EPS | ($0.137) | ($0.297) | ($0.220) | |
| # Rev Up | 1 | 1 | 0 | |
| # Rev Down | 0 | 0 | 1 | |
| Three Months Ago EPS | ($0.137) | ($0.297) | ($0.220) | |
| Year/Year Chg | 2.3% | (42.7%) | (13.3%) | |
| Financials | CGTX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $303 | na |
|
| Net Income (TTM) (Mil) | ($16) | ($10) | 25% |
|
| EPS (TTM) | ($0.176) | ($0.600) | 33% |
|
| Operating Cash Flow (TTM) (Mil) | ($15) | ($7) | 17% |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 14% |
|
| Enterprise Value (Q1) (Mil) | $34 | $408 | 14% |
|
| Valuation | CGTX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.19 | 2.19 | 58% |
|
| P/E | na | 22.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | CGTX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.5% | na |
|
| Net Margin | na | 3.9% | na |
|
| ROA | (40.9%) | (22.7%) | 13% |
|
| ROE | (48.6%) | (25.0%) | 15% |
|
| Liabilities to Assets | 15.9% | 31.8% | 10% |
|
| F-Score | 3 | 3 | 18% |
|
Cognition Therapeutics, Inc. did not pass any screens on 11/13/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors